PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Korean Journal of Internal Medicine10.3904/kjim.2017.22620193451100-1106Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapyMi Hwa Heo, Hee Kyung Kim, Hansang Lee, Ji-Yeon Kim, Jin-Seok Ahn, Young-Hyuck Im, Yeon Hee Parkhttp://kjim.org/upload/kjim-2017-226.pdf, http://kjim.org/journal/view.php?doi=10.3904/kjim.2017.226, http://kjim.org/upload/kjim-2017-226.pdf
Drugs10.1007/s40265-017-0855-52017781131-137Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine TherapyEmma D. Deekshttp://link.springer.com/article/10.1007/s40265-017-0855-5/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40265-017-0855-5.pdf, http://link.springer.com/content/pdf/10.1007/s40265-017-0855-5.pdf
Clinical Breast Cancer10.1016/s1526-8209(11)70173-2200232106-108Activity of Tipifarnib (R115777, Zarnestra™), a Farnesyl Transferase Inhibitor, in Previously Treated Metastatic Breast CancerKavita Maung, Vinay K. Jainhttps://api.elsevier.com/content/article/PII:S1526820911701732?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911701732?httpAccept=text/plain
Clinical Breast Cancer10.3816/cbc.2009.s.00620099S58-S65Evolving Approaches to Metastatic Breast Cancer Previously Treated with Anthracyclines and TaxanesConleth G. Murphy, Andrew D. Seidmanhttps://api.elsevier.com/content/article/PII:S1526820911706875?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911706875?httpAccept=text/plain
Clinical Breast Cancer10.1016/j.clbc.2019.11.0042019Metastatic Presentations of Previously Treated Early Stage Breast Cancer Patients and Association with SurvivalNajla Itani, Nicole Grogan, Sarah Mott, Sneha Phadkehttps://api.elsevier.com/content/article/PII:S1526820919307359?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820919307359?httpAccept=text/plain
Clinical Breast Cancer10.1016/j.clbc.2014.10.006201515290-100.e1Effectiveness of Targeted Therapy in Patients With Previously Untreated Metastatic Breast Cancer: A Systematic Review and Meta-AnalysisPaweł Kawalec, Sylwia Łopuch, Alicja Mikruthttps://api.elsevier.com/content/article/PII:S1526820914002262?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820914002262?httpAccept=text/plain
Breast Cancer10.1007/978-3-319-96947-3_242018533-555Endocrine Therapy of Metastatic Breast CancerFatma Sen, Adnan Aydinerhttp://link.springer.com/content/pdf/10.1007/978-3-319-96947-3_24
Clinical Breast Cancer10.1016/j.clbc.2013.10.008201414275-84Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of ActionStefan Glückhttps://api.elsevier.com/content/article/PII:S1526820913002450?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820913002450?httpAccept=text/plain
Clinical Breast Cancer10.3816/cbc.2002.s.00420023S17-S20Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary ResultsJoyce O'Shaughnessy, Svetislava J. Vukelja, Thomas Marsland, Gary Kimmel, Suresh Ratnam, John Pippenhttps://api.elsevier.com/content/article/PII:S1526820911702816?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911702816?httpAccept=text/plain
Clinical Breast Cancer10.3816/cbc.2001.n.01020012147-51Activity of Pemetrexed (ALIMTA®, Multitargeted Antifolate, LY231514) in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: An Interim AnalysisMarc Spielmann, Miguel Martin, Moïse Namer, Andreas duBois, Clemens Unger, David J. Dodwellhttps://api.elsevier.com/content/article/PII:S1526820911703214?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911703214?httpAccept=text/plain